Keep pulling the thread on Dr. Martinelli.
In a trial for chronic subdural hematoma, adjunctive embolization of the middle meningeal artery reduced symptomatic recurrence at 90 days to 4%, compared to 28% for surgical drainage alone.
The Tite randomized trial found no significant difference in six-month mortality between relaxed potassium supplementation (1.2% mortality) and tight control (1.1% mortality) after coronary bypass surgery.
In a clinical trial for neonatal opioid withdrawal, a symptom-based dosing strategy shortened the time to medical readiness for discharge by an average of just over two days.
An editorial by Dr. Grossman and colleagues suggests that symptom-based dosing combined with the EAT-Sleep Console assessment should be considered the new evidence-based standard for managing neonatal opioid withdrawal syndrome.
Dr. Bergman and colleagues propose a national licensure model for clinical artificial intelligence, similar to physician licensing, to ensure safety and avoid patchwork regulation.
In the U.S., one infant is diagnosed with neonatal opioid withdrawal every 27 minutes.
A cluster crossover randomized clinical trial led by Dr. Lori Devlin enrolled 626 infants at risk for neonatal opioid withdrawal across 23 U.S. hospitals.
In a trial on neonatal opioid withdrawal, 35% of pharmacologically treated infants in the symptom-based dosing group required a switch to scheduled opioid dosing.